| 成人急性髓系白血病治疗现状及新药研究进展 |
| |
| 引用本文： | 吴蒙莹,舒 婷,刘佳,江振洲,张陆勇. 成人急性髓系白血病治疗现状及新药研究进展[J]. 药学与临床研究, 2018, 26(4): 281-286 |
| |
| 作者姓名： | 吴蒙莹 舒 婷 刘佳 江振洲 张陆勇 |
| |
| 作者单位： | 中国药科大学，江苏省新药筛选重点实验室,中国药科大学，江苏省新药筛选重点实验室,中国药科大学，江苏省新药筛选重点实验室,中国药科大学，江苏省新药筛选重点实验室；药物质量与安全预警教育部重点实验室，中国药科大学,中国药科大学，江苏省新药筛选重点实验室；广东药科大学，药学院，新药筛选与药效学评价中心 |
| |
| 基金项目： | 国家自然科学基金面上项目（81274146） |
| |
| 摘 要： | 急性髓系白血病（Acute myeloid leukemia, AML）是一类高度异质性疾病，过去常规诱导化疗和各类支持治疗为主，但随着二代测序等技术应用以来，AML药物迅速发展。本文从细胞毒药物、小分子靶向药物以及免疫靶向药物等方面，系统概述AML的致病机制，以及临床研究中较为前沿的各类新型药物（如FLT3抑制剂Midostaurin、IDH抑制剂AG-221和CPX-351等）的研究进展，旨在为AML的新药研发提供参考。
|
| 关 键 词： | 急性髓系白血病；靶向治疗；新型药物 |
| 收稿时间： | 2018-03-24 |
| 修稿时间： | 2018-08-13 |
Treatment and Research Status of Adult Acute Myeloid Leukemia |
| |
| Wu Mengying,SHU Ting,LIU Ji,JIANG Zhen-zhou and ZHANG Lu-yong. Treatment and Research Status of Adult Acute Myeloid Leukemia[J]. Jiangsu Pharmacertical and Clinical Research, 2018, 26(4): 281-286 |
| |
| Authors: | Wu Mengying SHU Ting LIU Ji JIANG Zhen-zhou ZHANG Lu-yong |
| |
| Abstract: | Acute myeloid leukemia (AML) is a highly heterogeneous disease. Previously, AML treatment has been dominated by conventional induction chemotherapy and various supportive treatments, while new drug treatments for AML have been developed fast since the application of technologies such as second-generation sequencing. This article systematically summarizes the pathogenic mechanism of AML from the point of view of cytotoxic drugs, small molecule targeted drugs and immunotargeted drugs, and as well summarizes novel drugs that are more advanced in clinical research (such as the FLT3 inhibitor midostaurin, IDH inhibitors AG-221, and CPX-351), aiming to provide reference for the development of new drugs for AML. |
| |
| Keywords: | Acute myeloid leukemia Novel drug Targeted therapy |
|
| 点击此处可从《药学与临床研究》浏览原始摘要信息 |
|
点击此处可从《药学与临床研究》下载全文 |
|
